Cited by 843Myeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and TreatmentsAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Open access

Jones, A. V.·2005·Blood

DOI 10.1182/blood-2005-03-1320

Open this paper in CoChat — free account Open PDF

Abstract

The analysis of rare chromosomal translocations in myeloproliferative disorders has highlighted the importance of aberrant tyrosine kinase signaling in the pathogenesis of these diseases. Here we have investigated samples from 679 patients and controls for the nonreceptor tyrosine kinase JAK2 V617F mutation. Of the 480 myeloproliferative disorder (MPD) samples, the proportion of positive cases per disease subtype was 30 (20%) of 152 for atypical or unclassified MPD, 2 of 134 (2%) for idiopathic hypereosinophilic syndrome, 58 of 72 (81%) for polycythemia vera, 24 of 59 (41%) essential thrombocythemia (ET), and 15 of 35 (43%) for idiopathic myelofibrosis. V617F was not identified in patients with systemic mastocytosis (n = 28), chronic or acute myeloid leukemia (n = 35), secondary erythrocytosis (n = 4), or healthy controls (n = 160). Homozygosity for V617F was seen in 43% of mutant samples and was closely correlated with chromosome 9p uniparental disomy. Homozygosity was significantly less common in ET compared with other MPD subtypes. In 53 cases analyzed, the median level of PRV1 expression was significantly higher in V617F-positive cases compared with cases without the mutation. We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-03-1320

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860

Show all 0 references

Research works printed but not linked: 47

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-302.
Thiele J, Kvasnicka HM. Chronic myeloprolifera- tive disorders with thrombocythemia: a compara- tive study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82: 148-152.
Goldman JM, Melo JV. Chronic myeloid leuke- mia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002;16:1207-1212.
Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonal- ity in a human mast cell neoplasm. Nat Genet. 1996;12:312-314.
Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [letter]. N Engl J Med. 1974; 290:1382.
Dai CH, Krantz SB, Means RT Jr, Horn ST, Gil- bert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest. 1991;87:391-396.
Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310-3321.
Giraudier S, Chagraoui H, Komura E, et al. Over- expression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood. 2002;100: 2932-2940.
Komura E, Chagraoui H, Mansat de Mas V, et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpres- sion. Exp Hematol. 2003;31:622-630.
Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin- independent differentiation of erythroid progeni- tors in polycythemia vera. Exp Hematol. 2004;32: 179-87.
Silva M, Richard C, Benito A et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564- 571.
Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29:694-702.
James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive sig- nalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloprolif- erative disorders.N Engl J Med. 2005;352:1779- 1790.
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.
Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycy- themia vera, essential thrombocythemia, and my- eloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397
Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of real-time quantitative reverse transcriptase poly- merase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Eu- rope Against Cancer program. Leukemia. 2003; 17:2318-2357.
Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid se- quences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
Bunyan DJ, Eccles DM, Sillibourne J, et al. Dos- age analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 2004;91:1155-1159.
Hochberg EP, Miklos DB, Neuberg D, et al. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hemato- poietic chimerism after allogeneic stem cell trans- plantation. Blood. 2003;101:363-369.
Kralovics R, Guan Y, Prchal JT. Acquired unipa- rental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hema- tol. 2002;30:229-236.
Kralovics R, Passamonti F, Liu K, et al. loss of heterozygosity on chromsome 9p24 is the most frequent chromosomal aberration in polycythemia vera and idiopathic myelofibrosis [abstract]. Blood. 2005;104:666a.
Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythe- mia rubra vera. Blood. 2000;95:2569-2576.
Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003; 102:1869-1871.
Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood. 2004;103:3547- 3548.
Griesshammer M, Klippel S, Strunck E, et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol. 2004;83:364-370.
Saharinen P, Vihinen M, Silvennoinen O. Autoin- hibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell. 2003;14:1448-1459.
Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001;14:27-37.
Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus ki- nase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 1995;14:2857- 2865.
Lacronique V, Boureux A, Valle VD, et al. A TEL- JAK2 fusion protein with constitutive kinase activ- ity in human leukemia. Science. 1997;278:1309- 1312.
Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the re- ceptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leu- kemia. Blood. 1997;90:2535-2540.
Reiter AJ, Walz C, Watmore A, et al. The t(8; 9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662-2667.
Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Me- tastasis Rev. 2003;22:423-434.
Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cyto- kine receptors. Cell. 1998;93:385-395.
Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myelopro- liferative disorders. Blood Rev. 2005;19:1-13.
Spivak JL. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. Semin Hematol. 2003;40:1-5.
Harrison CN, Gale RE, Machin SJ, Linch DC. A larger proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417-424.
Bench AJ, Cross NCP, Huntly BJ, Nacheva EP, Green AR. Myeloproliferative disorders. Best Pract Res Clin Haematol. 2001;14:531-551.
Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haema- tol. 2002;119:558-566.
Reilly JT. Cytogenetic and molecular genetic as- pects of idiopathic myelofibrosis. Acta Haematol. 2002;108:113-119.
Irving JA, Bloodworth L, Bown NP, et al. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res. 2005;65:3053-3058.
Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental dis- omy due to somatic recombination in acute my- eloid leukemias. Cancer Res. 2005;65:375-378.
Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65-68.
Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995; 270:797-800.
Sandberg EM, Wallace TA, Godeny MD, Vonder- linden D, Sayeski PP. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem Biophys. 2004;41: 207-232.

Sorted by citations

Items 601–700 of 762

A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro
Chen, Y., Zhao, H., Luo, J., Liao, Y.-P., Tan, K., & Hu, G.-Y. (2021) · Oncology Letters · doi:10.3892/ol.2021.12612 · Cited by 3
SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms
Trifa, A., Lighezan, D., Jucan, C., Tripon, F., Arbore, D. R., Bojan, A., Gligor-Popa, Ș., Pop, R., Dima, D., & Bănescu, C. (2020) · doi:10.2478/rrlm-2020-0025 · Cited by 3
“a tetra-primer PCR until 2015, or detected and quantified using a real-time PCR assay thereafter (23,24).”
Method
Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature.
Mousinho, F., Santos, P. S. E., Azevedo, A., Pereira, J., Lemos, R., Matos, S., Viana, J., & Lima, F. (2018) · Molecular and clinical oncology · doi:10.3892/mco.2018.1682 · Cited by 3
“MPNs represent a group of heterogeneous chronic conditions, in which the main picture is characterized by medullary proliferation of at least one myeloid lineage, and increased number of mostly mature elements in the peripheral blood (7).”
A rare vascular complication in a patient with essential thrombocythaemia: spontaneous abdominal aortic dissection
Chen, Y., Han, X., Wang, F., Bai, B.-B., & Wang, Y. (2017) · Internal medicine journal (Print) · doi:10.1111/imj.13407 · Cited by 3
The JAK2V617F mutation in normal individuals takes place in differentiating cells.
Krichevsky, S., Prus, E., Perlman, R., Fibach, E., & Ben-yehuda, D. (2017) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2017.01.001 · Cited by 3
Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population
Park, S., & Ha, J.-S. (2015) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12328 · Cited by 3
“The unique somatic point mutation, Janus kinase 2 (JAK2) V617F, was discovered in MPNs, and >95% PV cases and approximately 60% of ET and PMF patients harbor this JAK2 mutation, which affects the JAK-signal transducers and activators of transcription (STAT) signaling pathway [2].”
Background
Association of the ACE I/D Gene Polymorphisms with JAK2V617F-Positive Polycythemia Vera and Essential Thrombocythemia
Gorukmez, O., Sag, S., Görükmez, Ö., Ture, M., Topak, A., Sahinturk, S., Ozkaya, G., Gulten, T., Ali, R., & Yakut, T. (2015) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0334 · Cited by 3
“Polycythemia vera (PV), essential thrombocytosis (ET), and primary myeloﬁbrosis are the most common BCR-ABL fusion gene-negative myeloproliferative neoplasms (Jones et al. , 2005).”
Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients.
Hsiao, H., Liu, Y.-C., Yang, M.-Y., Tsai, Y.-F., Liu, T.-C., Chang, C.-C., & Lin, S.-K. (2013) · Genetics and Molecular Research · doi:10.4238/2013.november.18.10 · Cited by 3
“The JAK2V617F mutation was identified by the amplification refractory mutation system (ARMS) (Jones et al., 2005).”
BackgroundMethod
Role of Signaling Pathways in Acute Myeloid Leukemia
Abdullah, M., & Sem, Z. (2011) · InTech eBooks · doi:10.5772/39093 · Cited by 4
“(Jones et al., 2005).”
JAK2 mutations in myeloproliferative neoplasms
Gangat, N., & Tefferi, A. (2011) · doi:10.4267/2042/44548 · Cited by 3
“JAK2 exon 12 mutations A small proportion of patients with PV are JAK2V617F negative when tested by sensitive allelespecific assays (Jones et al., 2005).”
JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies
Kreft, A., Kindler, T., Springer, E., & Kirkpatrick, C. (2011) · Virchows Archiv · doi:10.1007/s00428-011-1154-2 · Cited by 3
“In contrast to bcr– abl, the JAK2 mutation does not result in a distinct entity or phenotype but can be detected in the three most common Ph-negative MPNs with different frequencies; as a constant finding in polycythemia vera (PV) and in about half of the patients with essential thrombocythaemia (ET) and primary myelo…”
Background
[JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
Spasovski, V., Tošić, N., Kostić, T., Pavlovic, S., & Čolović, M. (2010) · Srpski Arhiv za Celokupno Lekarstvo · doi:10.2298/sarh1010614s · Cited by 3
Molecular characterization of chronic myeloproliferative neoplasias in México
Ruiz-Argüelles, G., Garcés‐Eisele, J., Ortíz-López, R., Rivas-Llamas, R., Gómez-Almaguer, D., & Ruiz-Delgado, G. (2009) · Hematology · doi:10.1179/102453309x439836 · Cited by 3
Phenotype and genotype in the myeloproliferative disorders
Spivak, J. L. (2007) · European journal of haematology. Supplementum · doi:10.1111/j.1600-0609.2007.00936.x · Cited by 3
“These findings were consistent with other studies suggesting that JAK2 V617F is observed with the greatest frequency in PV (12).”
Result
A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2V617F
Tefferi, A. (2006) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-006-0027-2 · Cited by 3
Quantification of clonal hematopoiesis in polycythemia vera
Siebolts, U., Ateş, M., Spitz, R., Thiele, J., & Wickenhauser, C. (2005) · Virchows Archiv · doi:10.1007/s00428-005-0047-7 · Cited by 3
Thrombocytosis
Altomare, I., & Kessler, C. (2019) · Consultative Hemostasis and Thrombosis · doi:10.1016/b978-0-323-46202-0.00019-4 · Cited by 3
The Frequency Of JAK2 V617F Gen Mutation And Its Associations With Whole Blood Count Parameters
Ünal, K., Erdoğan, S., & Yilmaz, F. (2014) · doi:10.5505/tjb.2014.39206 · Cited by 3
“Daha önce yayınlanmış çalışmalarda, JAK2 V617F mutasyon sıklığı PV olan hastalar için % 95, ET ve PMF için % 40-50 olarak belirlenmiştir [11].”
BackgroundInfluential
Molecular Testing in Hematologic Malignancies
Behdad, A., Betz, B. L., Lim, M. S., & Bailey, N. G. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8050-2_10 · Cited by 1
The Role of Janus Kinase 2 (JAK2) in the Pathologenesis of Myeloproliferative Disorders
Gari, M. A. (2009) · Journal of King Abdulaziz University-Medical Sciences · doi:10.4197/med.16-1.1 · Cited by 2
“Although, most patients with PV are JAK2 V617F are positive when assessed using appropriately sensitive allele-specific assays, a small proportion of patients with PV are negative for the JAK2 V617F allele([10,19,20,52]).”
Background
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi, A., Levine, R., & Kantarjian, H. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.10.010 · Cited by 3
“Subsequently, the mutation has also described in other myeloid neoplasms [65,66].”
Background
JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
Syeed, N. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.12.3611 · Cited by 2
Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1
Naumann, N., Dangelo, V., Lübke, J., Bresser, J., Hagen, V. A., Dengler, J. B., Metzgeroth, G., Kreil, S., Hockenberger, T., Hofmann, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11096-6 · Cited by 2
“Initial cytogenetic and/or FISH analysis revealed a typical t(9;22)(q34;q11) in 2/5 patients (#4, #5) and an atypical karyotype in 3/5 patients (#1: 46,XX[31]; #2: 46,XY,−5,+mar[2]/46,XY[15]; #3: 46,XY, der(11)t(9;11)(p21;p15)[7]/46,XY[8]).”
Association between JAK2V617F Mutation and Mean Platelet Volume among Myeloproliferative Neoplasm Patients
Khazeem, M., & Alwan, A. F. (2025) · Journal of Applied Hematology · doi:10.4103/joah.joah_42_25 · Cited by 2
Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients
Khazeem, M., & Alwan, A. F. (2024) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_46_24 · Cited by 2
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms
Carretta, C., Parenti, S., Bertesi, M., Rontauroli, S., Badii, F., Tavernari, L., Genovese, E., Malerba, M., Papa, E., Sperduti, S., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02373-w · Cited by 2
JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
Safavi, M., Monabati, A., Safaei, A., Mirtalebi, M., & Faghih, M. (2021) · Iranian Journal of Pathology · doi:10.30699/ijp.2021.136458.2495 · Cited by 2
“MPL is the receptor of thrombopoietin and has a pivotal role in megakaryopoiesis and platelet production (1-5).”
Background
Optimization of a Low-Cost, Sensitive PNA Clamping PCR Method for JAK2 V617F Variant Detection.
Francia, R. D., Crisci, S., Muto, T., Giancola, C., Petriccone, L., Catapano, O., Cummarro, A., Pinto, A., & Frigeri, F. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa041 · Cited by 2
Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017
Chatterjee, T., & Ahuja, A. (2018) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0913-x · Cited by 2
Hipk is required for JAK/STAT activity and promotes hemocyte-derived tumorigenesisPreprint
Blaquiere, J., Wray, N., & Verheyen, E. (2016) · bioRxiv · doi:10.1101/058156 · Cited by 2
“Dysregulation of the JAK/STAT pathway has been linked to leukemia, myeloproliferative neoplasms, and solid tumors in flies and vertebrates (Amoyel et al., 2014; Dearolf, 1998; Jones et al., 2005; Lacronique, 1997; Levine et al., 2005).”
Background
Genetically Engineered In Vitro Erythropoiesis
Geiler, C., Andrade, I., Clayton, A., & Greenwald, D. R. (2016) · International Journal of Stem Cells · doi:10.15283/ijsc.2016.9.1.53 · Cited by 3
“Patients with PV have a homozygous JAK2 V617F mutation, and patients with ET have a heterozygous mutation, indicating the dose dependent effect of the mutation (34).”
Background
Prevalence of JAK2 V617F mutation in west algerian population with chronic myeloproliferative neoplasms: A multicenter study
Benguella-Benmansour, M., Boucherit, K., Benchikh, N., Mesli, N., Chabni, N., Messaoudi, A., Bekadja, A., Boucherit, Z., & Mozziconacci, M. (2014) · doi:10.1007/s12558-014-0304-7 · Cited by 2
Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
Wu, H.-L., Bian, S., Chu, J., Zhong, X., Sun, H., Zhang, B.-C., & Lu, Z.-M. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.975 · Cited by 2
“as being positive in <20% of MDS/MPN patients (17); however, in this study, only one case was positive for the JAK2 gene among the five MDS/MPN cases.”
MGMT Gene Promoter Methylation Analysis by Pyrosequencing of Brain Tumour
Kim, Y. Z., Song, Y.-J., Kim, K. U., & Kim, D. C. (2011) · doi:10.4132/koreanjpathol.2011.45.5.455 · Cited by 2
JAK2 46/1 haplotype seems not to be associated with lower limb deep venous thrombosis.
Trifa, A., Criṣan, S., Popp, R., Cucuianu, A., & Buzoianu, A. (2010) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2010.07.004 · Cited by 2
No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients
Politou, M., Zoi, C., Dahabreh, I., Rallidis, L., Gialeraki, A., Loukopoulos, D., & Zoi, K. (2009) · Leukemia · doi:10.1038/leu.2008.368 · Cited by 2
“The JAK2 V617F mutation was detected using a tetra-primer amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) assay with a sensitivity of 1p”
Method
Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation.
Spanoudakis, E., Margaritis, D., Kotsianidis, I., Georgiou, G., Tripsianis, G., Anastasiadis, A., Karakolios, A., Pantelidou, D., Panayiotidis, P., Bourikas, G., et al. (2008) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2008.01.013 · Cited by 2
Switch in X-inactivation in a JAK2 V617F-negative case of polycythemia vera with two acquired X-autosome translocations.
Manola, K., Stavropoulou, C., Georgakakos, V. N., Zoi, K., Fisfis, M., Evmorfiadis, I., Zoi, C., Pantelias, G., Stefanoudaki, K., & Sambani, C. (2007) · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · doi:10.1016/j.leukres.2006.11.014 · Cited by 2
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
Silver, R. (2007) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-007-0006-2 · Cited by 2
“The recent finding of a molecular abnormality, the JAK2 V617F mutation, in more than 95% of patients with PV suggests that this mutation may be exploited in order to measure the response to rIFNB or imatinib of patients with PV, particularly those who have responded clinically [ 24 ].”
Background
Chapter 25 – Molecular Hematopathology
Cook, J. (2009) · doi:10.1016/b978-044306901-7.50030-4 · Cited by 2
Germline predisposition in myeloproliferative neoplasms.
Chernoff, M., & Drazer, M. (2026) · Seminars in hematology (Print) · doi:10.1053/j.seminhematol.2026.06.006 · Cited by 1
The frequency of JAK2 V617F mutation and its association with low EPO levels in polycythemia vera patients
Aci, R., Keskin, A., Sezer, Ö., Karakaya, T., Semiz, S., & Kızılet, H. (2025) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2025.2502945 · Cited by 1
A Software Tool for Reagent Design to Expand Access to Single-Nucleotide Variant Detection by the Oligonucleotide Ligation Assay
Nelson, D. J., Chugh, K., Pua, H., & Haselton, F. R. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.12.007 · Cited by 1
Frequency of Calreticulin Genotype among JAK2V617F-negative Patients Suspected with Essential Thrombocythemia
Khazeem, M., & Alwan, A. F. (2024) · Journal of Applied Hematology · doi:10.4103/joah.joah_72_24 · Cited by 1
The Role of DNA Repair (XPC, XPD, XPF, and XPG) Gene Polymorphisms in the Development of Myeloproliferative Neoplasms
Crișan, A., Tripon, F., Bogliș, A., Crauciuc, G., Trifa, A., Lázár, E., Macarie, I., Gabor, M., & Bănescu, C. (2024) · Medicina · doi:10.3390/medicina60030506 · Cited by 1
“JAK2 V617F and CALR mutations were performed as presented in previous papers [7,49,50].”
Method
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
Ligia, S., Scalzulli, E., Carmosino, I., Palumbo, G., Molinari, M. C., Poggiali, R., Costa, A., Bisegna, M., Martelli, M., & Breccia, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1338417 · Cited by 1
“Canonical JAK2 V617F and exon 12 mutations in MPNs are well described (1, 2).”
Background
A novel germline hyperactivating JAK2 mutation L604F
Dvořáček, L., Marková, J., Holoubek, A., Grebeňová, D., Kundrát, D., Kuželová, K., & Schwarz, J. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05423-y · Cited by 1
Polymerase chain reaction-restriction fragment length polymorphism method for detection of Calreticulin type-1 and type-2 mutations in myeloproliferative neoplasm
Naseem, S., Binota, J., Varma, N., Satyarthi, P., Rana, P., & Malhotra, P. (2021) · Journal of Hematopathology · doi:10.1007/s12308-021-00462-8 · Cited by 1
“JAK2V617F mutation status was tested in all samples by amplification refractory mutation system PCR (ARMSPCR) [17].”
Method
A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina
Kurtović-Kozarić, A., Islamagić, E., Ašić, A., Mehinovic-Cavcic, L., Bešić, L., Sahinbegovic, H., Komic, H., Kurtovic, S., & Burazerović, L. (2021) · Acta Medica Academica · doi:10.5644/ama2006-124.334 · Cited by 1
“(2005) involves two outer control primers (FO and RO) which are complementary to the region flanking exon 14 of the JAK2 gene, while the inner primers are complementary to the region flanking the G (in case of a wild-type sequence) or the T (in case of a mutation) (83).”
Background
Prevalence of JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms
Hamid, M., & Shahbazi, Z. (2020) · doi:10.22037/amls.v6.32758 · Cited by 1
“JAK2 V617F is occasionally detected in leukemia or other bone marrow disorders and related disease (7).”
Background
Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm
Atere, M., Al-Zakhari, R., Collins, J., Rotatori, F., & Muzangwa, L. (2020) · Case Reports in Oncological Medicine · doi:10.1155/2020/9654048 · Cited by 1
Study of the p.V617F and Exon 12 Mutations in JAK2 Gene Among Iranian Chronic Myeloproliferative Patients
Khatamianfar, S., Akbari, M., Karizi, S. Z., & Deilamani, F. K. (2019) · doi:10.5812/jhgg.88293 · Cited by 1
Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera
Kajikawa, N., Seki, Y., Fujio, T., Okoshi, Y., Hori, M., Saito, H., Iijima, T., & Kojima, H. (2018) · Internal medicine · doi:10.2169/internalmedicine.1093-18 · Cited by 1
“The discovery of the JAK2 V617F mutation, which is detectable in more than 95% of patients with PV, has clarified the molecular pathogenesis of this disorder (1-5).”
Background
Myeloproliferative Neoplasms: Essential Thrombocythemia, Primary Myelofibrosis, and Polycythemia Vera
Tefferi, A. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm123 · Cited by 2
Water Pollution and Leukemia: A Model for Interdisciplinary Research in the Classroom Experiences Incorporating Effective Pedagogical Approaches for Community College General Biology I Lab Students
Xu, N., Porter-Morgan, H., Doran, N., & Keller, C. (2016) · doi:10.5430/ijhe.v5n4p122 · Cited by 1
Estimate of JAK 2 V617F Mutation and Activity of Catalase Enzyme in Myeloproliferative Neoplasm
Abdullah, H., Saifullah, P., Shebib, Z. A., & Abdullah, A. (2016) · doi:10.22401/jnus.19.3.01 · Cited by 1
“& Amy; who found JAK2 V617F mutation are present (81%), (<90%) and (82%) in PV patients Consecutive [8],[16],[17].”
BackgroundInfluential
Advances in the Diagnosis of Myeloproliferative Neoplasms
Jang, M.-A., & Choi, C. (2016) · doi:10.3904/kjm.2016.90.4.281 · Cited by 1
The Prevalence of JAK2-V617F Mutation in Sudanese Patients with Chronic Myeloproliferative Neoplasms
Abkar, H., Mohamed, B., & Hassan, F. (2016) · doi:10.9734/bjmmr/2016/24741 · Cited by 1
Melting curve アッセイとamplification refractory mutation system (ARMS)法によるJAK2 V617F変異の検出感度の比較
福塚, 勝., 竹岡, 加., 林田, 雅., 前川, ふ., 中村, 文., & 大野, 仁. (2013) · doi:10.12936/tenrikiyo.16-014 · Cited by 1
JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture
Hasan, S. (2013) · theses.fr (ABES) · doi:10.70675/e7b6a27fz4fc4z4352z8799zc191ba7d177d
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
Merx, K., Fabarius, A., Erben, P., Griesshammer, M., Reiter, A., Hofmann, W., Hehlmann, R., Hochhaus, A., & Lengfelder, E. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1725-1 · Cited by 1
Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloproliferative Neoplasms
Sholl, L., & Longtine, J. (2010) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1004s67 · Cited by 1
“Because the V617F mutation is present in the vast majority of cases, it is amenable to targeted analysis using a simple and sensitive PCR approach (Jones et al., 2005)–amplification refractory mutation system (ARMS), a form of allele-specific PCR. NOTE: IPSOGEN (Marseilles, France) has developed a…”
BackgroundMethod
Comparison of JAK2 V617F burden quantitation by two different quantitative‐polymerase chain reaction methods
Bars, H. L., Boulland, M.-L., Bareau, B., Grosbois, B., Corolleur, M., Lamy, T., & Fardel, O. (2010) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2010.01209.x · Cited by 1
“…status was initially assessed on peripheral blood granulocyte DNA using the qualitative amplification refractory mutation system PCR assay (Jones et al., 2005); diagnosis was available for 50 of these 58 patients (polycythemia vera, n = 31; essential thrombocythemia, n = 17; primary…”
Method
Role of IL12 Family in Regulation of Antitumor Immune Response
Dibra, D., & Li, S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0170-5_1
Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms and Related Conditions
MBBS, F. B. J. B., Clark, M. D. M., & DM, B. S. W. (2009) · Bone Marrow Pathology · doi:10.1002/9781444309782.ch5 · Cited by 2
JAK2 V617F MUTATION AND PRV-1 OVEREXPRESSION: RELEVANCE IN THE DIAGNOSIS OF POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA
Melis, S., Vellinga, S., Zachée, P., Sierens, A., & Schouwer, P. D. (2009) · Acta Clinica Belgica · doi:10.1179/acb.2009.070 · Cited by 1
“Prior splenectomy In 2005, several groups described the presence of an acquired point mutation in the pseudokinase domain of Janus kinase 2 gene (JAK2 V617F) in patients suffering a myeloproliferative disorder(13-18).”
BackgroundMethod
Chronische Myeloproliferative Erkrankungen (CMPE)
Rechberger, E., Webersinke, G., & Petzer, A. (2008) · doi:10.1007/s11812-008-0036-2 · Cited by 1
Application of growth factor stimulants improves cytogenetic analysis of chronic myeloproliferative disorder patients without alteration to cell lineage or clonality.
Vaughan, B., Scott, M., Nacheva, E. P., & Howard, J. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.02.001 · Cited by 1
Myelodysplastic/Myeloproliferative Disorder Overlap Syndrome: How Should it be Approached?
Litzow, M. (2006) · doi:10.3816/clk.2006.n.014 · Cited by 1
Mutation de la protéine kinase JAK2 au cours de la polyglobulie de Vaquez : nouvelles perspectives physiopathologiques et thérapeutiques
Marie, I., & Hervé, F. (2006) · doi:10.1016/j.revmed.2006.02.011 · Cited by 1
Inconsistencies in the association between JAKV617F mutation and PRV‐1 over‐expression among the chronic myeloproliferative disorders – response to Vannucchi et al
Tefferi, A. (2006) · doi:10.1111/j.1365-2141.2005.05950.x · Cited by 1
V617F “JAKs” up myeloproliferative signal
Tefferi, A. (2005) · doi:10.1182/blood-2005-08-3352 · Cited by 1
Importance of molecular confirmation in the diagnosis of myeloproliferative disorders
Slater, D., Ronski, K., Delach, J. A., Benn, P., & Fang, M. (2005) · doi:10.1016/s1548-5315(11)70616-7 · Cited by 1
Molecular Testing in Myeloproliferative Neoplasms
Furtado, L. V., & Betz, B. (2017) · doi:10.1016/b978-0-12-800886-7.00034-0 · Cited by 1
The Evaluation of Cardiac Disorders and Systemic Hypertension in JAK 2 V 617 F Positive Patients at a Multicenter Institution
Tuchayi, A. M., Sheth, S., & Smith, R. E. (2016) · doi:10.13188/2380-6842.1000014 · Cited by 1
“The JAK2 V617F point mutation has been reported in more than 90% of patients with polycythemia vera (PV) and approximately half of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET) [2-5].”
Background
Frequency and Clinicohematologic Characteristics of MPL W515 Mutations in Patients with Myeloproliferative Neoplasms
Park, S., Kim, K., Lee, W., Ha, J., Ryoo, N., Jeon, D., Kim, J. R., Ham, J., Jang, S.-S., & Kim, Y. K. (2015) · doi:10.3343/lmo.2015.5.1.1 · Cited by 1
Chronic Myeloid Leukaemias
Bain, B. (2013) · doi:10.1002/9781444318470.ch5 · Cited by 1
Molecular Methods in Myeloproliferative Neoplasms
Leszczyńska, A., Prejzner, W., Bieniaszewska, M., & Hellmann, A. (2012) · Principles and practice · doi:10.1007/978-3-642-29467-9_28 · Cited by 1
“The most commonly used method in the routine laboratory setting is amplification refractory mutation system polymerase chain reaction (ARMS-PCR) (Jones et al. 2005; Chen et al. 2007).”
Method
Principles of Classification of Myeloid Neoplasms
Arber, D., & Vardiman, J. (2011) · doi:10.1016/b978-0-7216-0040-6.00043-5 · Cited by 1
Cancer Gene Profiling
Grützmann, R., & Pilarsky, C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-59745-545-9 · Cited by 1
The role of FasR/FasL system in pathogenesis of myeloprolyferative neoplasms
Spasovski, V., Tos̆ić, N., Kostić, T., Zukić, B., Stojiljković, M., Čolović, M., & Pavlović, S. (2010) · Archives of Biological Sciences · doi:10.2298/abs1002223s · Cited by 1
Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan
Mori, N., Yoshinaga, K., Tada, M., Wang, Y.-H., Shiseki, M., & Motoji, T. (2008) · doi:10.1590/s1415-47572008000300006 · Cited by 1
“Other recent studies found a similar incidence of the V617F mutation: 0/17 (Jones et al., 2005), 5/90 (6%) (Scott et al.”
Background
Polycythemia vera and other polycythemia syndromes.
Silver, R. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-73744-7_1 · Cited by 1
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5
Guru, S. A., Sumi, M. P., Mir, R., Waza, A. A., Bhat, M. A., Zuberi, M., Lali, P., & Saxena, A. (2020) · Human Cell · doi:10.1007/s13577-020-00370-6 · Cited by 16
Translocation t(3;12)(q26;q21) In Jak2V617F Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report
S, M., H., Š., & M, P. (2014) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2014-0026
Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications
Huang, J., Yin, X., Shi, X., Xiu-di, Y., Li, R., Zhang, X., Zhang, Y., Tong, H., Jin, J., & Huang, J. (2026) · Biomarker Research · doi:10.1186/s40364-026-01003-0
“Janus kinase 2 ( JAK2 ) driver mutations, especially JAK2 V617F , constitute a major molecular basis for MPNs [1–3].”
The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility
McCaul, N., Bingham, R. J., & Blann, A. D. (2026) · British Journal of Biomedical Science · doi:10.3389/bjbs.2025.14745
Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis
Pan, Y., Chen, L.-Y., Jiang, Q., Chen, D.-J., Wu, Y.-Q., Hou, L., Lang, H., & Yan, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02232-9
“Numerous groundbreaking studies have been featured in Blood , including but not limited to pivotal research on driver mutation [22, 23], key clinical data on ruxolitinib [24], and exploring best available therapies [25].”
The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia
Sayed, W. S., Al-bayati, A., Elzubair, L. G., Mohamed, S., & Alharthi, M. (2024) · Cureus · doi:10.7759/cureus.74401
Genetic analysis of driver mutations in classical myeloproliferative neoplasms – a study from a South Indian Tertiary Care Center
Pai, U. K. N., Sankarankutti, R. T., Rafi, A., John, M. C., Raj, S., Earali, J., & Raveendran, S. (2024) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_63_24
Exogenous Janus Kinase 617 Codon Influences Small Noncoding RNAs and Gene Expression in Ba/F3 Cells.
Chen, Y.-Y., Wang, Y.-H., Chen, C.-C., Huang, C.-E., Hsu, C.-C., Hsiao, S.-H., & Leu, Y. (2024) · Journal of physiological investigation · doi:10.4103/ejpi.ejpi-d-24-00047
Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.
Sobieralski, P., Bieniaszewska, M., Bołkun, Ł., Sacha, T., Muzalewska-Wolska, M., Homenda, W., Bartkowiak, Ł. K., Smith, J., Rymko, M., Jachalska, A., et al. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/182857
Clinical significance of low level JAK2 V617F in peripheral blood testing
Rubic, M., Lee, L., & STEVENSON, W. C. (2024) · Pathology · doi:10.1016/j.pathol.2023.10.026
COMPARISON OF PATIENTS WITH PRE-DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH LOW AND HIGH JAK2V617F ALLELE BURDEN IN TERMS OF CLINICAL AND HEMATOLOGICAL PARAMETERS
Erkal, O., Paksoy, B., & Patır, P. (2024) · Kocatepe Tıp Dergisi · doi:10.18229/kocatepetip.1254047
FREQUENCY OF CLAR AND JAK2 MUTATIONS IN SUDANESE CHRONIC MYELOID LEUKEMIA PATIENTS WITH PHILADELPHIA-POSITIVE DISEASE
Yasin, E. B., & Yasin, A. (2023) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2023.v16i8.48344
“More than 95% of patients with PV and more than 50% of patients with ET and IMF have this mutation [10-13].”
Background
Use of a New Structure of Fluorescent-Labeled DNA Oligonucleotides to Reveal Mutation JAK2 V617F During Development of Leukemia
Makhnev, A. A., Baimirzaev, A. B., Nasriddinov, K., Alimukhamedova, O., & Azimova, S. S. (2022) · Chemistry of Natural Compounds · doi:10.1007/s10600-022-03901-9
Impact of JAK2V617F Mutational on Haematologic Features in Sudanese Patients with Essential Thrombocythemia and Thrombotic Risk Assessment
Elbager, S., Bayoumi, M., Tohit, E., Dowd, A., & Lai, M. (2020) · doi:10.21608/jbaar.2020.128502
“A. S., TEO, S. S., TIEDT, R., PASSWEG, J. R., TICHELLI, A., CAZZOLA, M. & SKODA, R. C. 2005.”
PCR đặc hiệu allele tích hợp công nghệ amplification refractory mutation system (Dsa-Pcr-Arms) phát hiện đột biến jak2 v617f và Carl trên bệnh nhân có hội chứng tăng sản tủy
Ngô, T. T. (2020) · doi:10.38103/jcmhch.2020.59.8
Kronik Miyeloproliferatif Hastalık Olgularında JAK2 V617F Mutasyon Sıklığı
Öz, Ö. (2019) · doi:10.35440/hutfd.645383
Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities.
Kim, S. Y., Koo, M., Park, Y., Kim, H., Choi, Q., Song, I., Jo, D., Kim, J., Kwon, G., & Koo, S. (2019) · Blood Cells, Molecules & Diseases · doi:10.1016/j.bcmd.2019.04.007

Authors: Jones, A. V.
Affiliations: Cornell University (US)
Corresponding author: Jones, A. V.
ORCID: Jones, A. V.
Venue: Blood
Publisher: American Society of Hematology
Published: 2005-09-15
Volume: 106
Issue: 6
Pages: 2162-2168
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2005-03-1320
OpenAlex: W2126665281
Cited by: 843
References: 0
Citations by year: 2026: 4 · 2025: 6 · 2024: 17 · 2023: 22 · 2022: 12 · 2021: 19 · 2020: 21 · 2019: 30 · 2018: 15 · 2017: 21 · 2016: 32 · 2015: 47 · 2014: 38 · 2013: 46 · 2012: 40
FWCI: 43.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: JAK2 V617F mutation, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, primary myelofibrosis, idiopathic hypereosinophilic syndrome, tyrosine kinase signaling, mutation prevalence
MeSH terms: Chronic Disease, Female, Homozygote, Humans, Male, Myeloproliferative Disorders, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Signal Transduction, Prevalence, Case-Control Studies, Molecular Epidemiology, Microsatellite Repeats, Mutation, Missense, Janus Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks